On April 16, OpenAI announced GPT-Rosalind, a new AI model targeted at the life sciences. It significantly outperforms their current publicly available models in chemistry and biology tasks, as well as experimental design. As with Anthropic’s Claude Mythos and OpenAI’s GPT-5.4-Cyber, also released this month, the model is not available to the general public—reserved, at least initially, for “qualified customers” through a “trusted access program.”  The releases signal a new and concerning trend of AI companies deeming their most capable models too powerful to entrust to the general public. “I think frontier developers are restricting access to their most capable models because they are genuinely worried about some of the capabilities these models have,” says Peter Wildeford, head of policy at the AI Policy Network, an advocacy group.  It is unclear why OpenAI decided to restrict access to GPT-Rosalind in particular.…